MedTrace Logo

Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy

NCT00399776 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2011-08-04

No results posted yet for this study

Summary

We hypothesize that antipsychotic induced hyperprolactinemia can decrease bone mineral accrual and decrease bone mineral content (BMC) in adolescents on antipsychotic therapy.

Specifics Aims

1. To determine if antipsychotic therapy leads to decreased bone mineral accrual and decreased bone mineral content in a group of adolescents on antipsychotic therapy by comparing them to an ethnicity, gender and pubertal stage matched control group.
2. To determine the relationship between serum concentrations of prolactin, sex steroids and bone turnover markers in adolescents on antipsychotic therapy and an ethnicity, gender and pubertal stage matched control group.

Conditions

  • Adolescent Depression

Interventions

RADIATION

Bone Density Test

Evaluating bone mineral content and bone metabolism in adolescents on antipsychotic therapy compared to healthy adolescents

Sponsors & Collaborators

  • Thrasher Research Fund

    collaborator OTHER

  • Creighton University

    lead OTHER

Principal Investigators

  • Sriram Ramaswamy, M.D. · Creighton University

Eligibility

Min Age
10 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00399776 on ClinicalTrials.gov